Trial · NCT02408861
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 6 | |
| Overall Study | STARTED | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 9 | |
| Overall Study | STARTED | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 7 | |
| Overall Study | STARTED | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 4 | |
| Overall Study | STARTED | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 24 | |
| Overall Study | STARTED | Dose Expansion Nivolumab 240 mg q2w and Ipilimumab 1 mg/kg q6w | 20 | |
| Overall Study | STARTED | Nivolumab 240 mg q2w in Classical Hodgkin Lymphoma | 9 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 0 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 0 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 1 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 0 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 0 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Dose Expansion Nivolumab 240 mg q2w and Ipilimumab 1 mg/kg q6w | 0 | |
| Overall Study | Number of DLTs experienced within 6 weeks | Nivolumab 240 mg q2w in Classical Hodgkin Lymphoma | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose De-escalation Nivolumab 3mg/kg (Stratum 1) | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose De-escalation Nivolumab 3 mg/kg (Stratum 2) | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose De-escalation Nivolumab 240mg and Ipilimumab 1 mg/kg (Stratum 1) | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2) | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose Expansion Nivolumab 240 mg q2w in Solid Tumors | 0 | |
| Overall Study | Patients receiving de-escalated dose of Nivolumab (1 mg/kg) | Dose Expansion Nivolumab 240 mg q2w and Ipilimumab 1 mg/kg q6w | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408861/flow